132 related articles for article (PubMed ID: 31062077)
1. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
Pápai Z; Chen LC; Da Costa D; Blotner S; Vazvaei F; Gleave M; Jones R; Zhi J
Cancer Chemother Pharmacol; 2019 Jul; 84(1):93-103. PubMed ID: 31062077
[TBL] [Abstract][Full Text] [Related]
2. Effects of posaconazole (a strong CYP3A4 inhibitor), two new tablet formulations, and food on the pharmacokinetics of idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors.
Nemunaitis J; Young A; Ejadi S; Miller W; Chen LC; Nichols G; Blotner S; Vazvaei F; Zhi J; Razak A
Cancer Chemother Pharmacol; 2018 Mar; 81(3):529-537. PubMed ID: 29368050
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 summary of plasma concentration-QTc analysis for idasanutlin, an MDM2 antagonist, in patients with advanced solid tumors and AML.
Blotner S; Chen LC; Ferlini C; Zhi J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):597-607. PubMed ID: 29392451
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
7. Lack of UGT polymorphism association with idasanutlin pharmacokinetics in solid tumor patients.
So WV; Ou Yang TH; Yang X; Zhi J
Cancer Chemother Pharmacol; 2019 Jan; 83(1):209-213. PubMed ID: 30511219
[TBL] [Abstract][Full Text] [Related]
8. Oral idasanutlin in patients with polycythemia vera.
Mascarenhas J; Lu M; Kosiorek H; Virtgaym E; Xia L; Sandy L; Mesa R; Petersen B; Farnoud N; Najfeld V; Rampal R; Dueck A; Hoffman R
Blood; 2019 Aug; 134(6):525-533. PubMed ID: 31167802
[TBL] [Abstract][Full Text] [Related]
9. Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆.
Yee K; Papayannidis C; Vey N; Dickinson MJ; Kelly KR; Assouline S; Kasner M; Seiter K; Drummond MW; Yoon SS; Lee JH; Blotner S; Jukofsky L; Pierceall WE; Zhi J; Simon S; Higgins B; Nichols G; Monnet A; Muehlbauer S; Ott M; Chen LC; Martinelli G
Leuk Res; 2021 Jan; 100():106489. PubMed ID: 33302031
[TBL] [Abstract][Full Text] [Related]
10. Accelerating Clinical Development of Idasanutlin through a Physiologically Based Pharmacokinetic Modeling Risk Assessment for CYP450 Isoenzyme-Related Drug-Drug Interactions.
Umehara K; Cleary Y; Fowler S; Parrott N; Tuerck D
Drug Metab Dispos; 2022 Mar; 50(3):214-223. PubMed ID: 34937801
[TBL] [Abstract][Full Text] [Related]
11. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
12. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Corbali MO; Eskazan AE
Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
[No Abstract] [Full Text] [Related]
13. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
14. Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans.
Glenn KJ; Yu LJ; Reddy MB; Fretland AJ; Parrott N; Hussain S; Palacios M; Vazvaei F; Zhi J; Tuerck D
Xenobiotica; 2016 Aug; 46(8):667-76. PubMed ID: 26586447
[TBL] [Abstract][Full Text] [Related]
15. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Chen L; Pastorino F; Berry P; Bonner J; Kirk C; Wood KM; Thomas HD; Zhao Y; Daga A; Veal GJ; Lunec J; Newell DR; Ponzoni M; Tweddle DA
Int J Cancer; 2019 Jun; 144(12):3146-3159. PubMed ID: 30536898
[TBL] [Abstract][Full Text] [Related]
17. Efficient Industrial Synthesis of the MDM2 Antagonist Idasanutlin via a Cu(I)-catalyzed [3+2] Asymmetric Cycloaddition.
Fishlock D; Diodone R; Hildbrand S; Kuhn B; Mössner C; Peters C; Rege PD; Rimmler G; Schantz M
Chimia (Aarau); 2018 Aug; 72(7):492-500. PubMed ID: 30158012
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
Reis B; Jukofsky L; Chen G; Martinelli G; Zhong H; So WV; Dickinson MJ; Drummond M; Assouline S; Hashemyan M; Theron M; Blotner S; Lee JH; Kasner M; Yoon SS; Rueger R; Seiter K; Middleton SA; Kelly KR; Vey N; Yee K; Nichols G; Chen LC; Pierceall WE
Haematologica; 2016 May; 101(5):e185-8. PubMed ID: 26869629
[No Abstract] [Full Text] [Related]
19. Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
Patnaik A; Tolcher A; Beeram M; Nemunaitis J; Weiss GJ; Bhalla K; Agrawal M; Nichols G; Middleton S; Beryozkina A; Sarapa N; Peck R; Zhi J
Cancer Chemother Pharmacol; 2015 Sep; 76(3):587-95. PubMed ID: 26210682
[TBL] [Abstract][Full Text] [Related]
20. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Johne A; Scheible H; Becker A; van Lier JJ; Wolna P; Meyring M
Invest New Drugs; 2020 Oct; 38(5):1507-1519. PubMed ID: 32221754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
